BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
+0.28 (1.94%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.42 - 15.07
52 week 6.71 - 18.48
Open 14.73
Vol / Avg. 1.21M/717,601.00
Mkt cap 754.42M
P/E     -
Div/yield     -
EPS -1.09
Shares 51.29M
Beta 2.37
Inst. own 83%
Mar 12, 2015
Q4 2014 BioDelivery Sciences International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 9, 2015
BioDelivery Sciences International Inc at ROTH Conference - 12:00PM EDT - Add to calendar
Feb 24, 2015
BioDelivery Sciences International Inc at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1385.90% -505.41%
Operating margin -1045.82% -496.68%
EBITD margin - -484.81%
Return on average assets -98.87% -100.92%
Return on average equity -174.76% -234.45%
Employees 24 -
CDP Score - -


Suite 210 801 Corporate Center Drive
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company. BDSI is developing and commercializing, either on its own or in partnerships with third parties, applications of therapeutics to address medical needs. The Company has developed and is continuing to develop pharmaceutical products aimed principally in the areas of pain management and oncology supportive care. In formulating the Company's products and product candidates, BDSI utilizes the BioErodible MucoAdhesive (BEMA) drugs delivery technology, a small, erodible polymer film for application to the buccal mucosa. The Company's the United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its pipeline of product candidates, utilize its BEMA technology.

Officers and directors

Frank E. O'Donnell Jr. MD Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Mark A. Sirgo Pharm.D. President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Ernest R. De Paolantonio CPA Chief Financial Officer, Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Andrew L. Finn Pharm.D. Executive Vice President - Product Development
Age: 65
Bio & Compensation  - Reuters
James A. McNulty CPA Senior Vice President - Finance, Treasurer
Age: 62
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Charles J. Bramlage Director
Bio & Compensation  - Reuters
Thomas W. D'Alonzo Director
Age: 71
Bio & Compensation  - Reuters
Barry I. Feinberg M.D. Director
Bio & Compensation  - Reuters
Samuel P. Sears Jr. Independent Director
Age: 70
Bio & Compensation  - Reuters